Alpha-Mannosidosis
New alpha-mannosidosis research, summarized each month in plain language.
2026 so far: So far in 2026 (January 2026 to September 2026), real-world and case reports added detail on velmanase alfa outcomes and infusion reactions, alongside new urine biomarkers and early late-stage gene-therapy animal data. Read the 2026 review
We also cover clinical trials.
Yearly update
2026 so far
- Velmanase alfa in routine care. Evidence moved from single cases to small registry observations.
- Gene therapy in late-stage disease. Animal data suggested benefit in late disease, with a dose ceiling.
- Urine biomarkers for follow-up. Biochemical monitoring advanced from concept to a reported test.
- Tools for tracking change. Research emphasized more standardized growth and lived-experience measures.
- Diagnosis and eye findings. Clinical reports added detail on delays and progressive eye changes.
New
September 2026
- Everyday treatment effects. Velmanase alfa was linked to better movement and wellbeing scores.
- Charted symptom changes. Recorded health problems were described as stable or improved over time.
- Infusion side effects. Treatment-related side effects occurred in 3 of 16 patients; one stopped after severe infusion reactions.
August 2026
- Enzyme therapy report. One child on velmanase alfa improved movement and language.
- Hearing over time. Hearing was reported as stable over 12 months.
- Reported side effects. No treatment-related side effects were reported in that child.
- Fruit fly disease model. A fruit fly model linked a pathway to less lysosome workload.
June 2026
- Eye test results. Eye imaging and retina function tests helped explain vision changes.
- Dim-light response. Retina testing was abnormal in dim light, not bright light.
- Teen eye findings. One teen had reduced vision with retina and optic nerve changes.
May 2026
- Urine test separates cases. A lab urine test distinguished people with alpha-mannosidosis from controls, supporting a clearer way to measure disease-related buildup.
- Urine marker shifts after treatment. One urine marker differed in treated versus untreated people after enzyme replacement therapy or stem cell transplant.
- Gene therapy in late-stage cats. In a cat model of late-stage alpha-mannosidosis, gene therapy was linked to partial improvement and longer survival compared with untreated cats.
February 2026
- Automated bone age readings. Software that reads hand X-rays estimated bone age about as well as an expert consensus and, in comparisons, better than single expert readers, which may support more consistent growth tracking across clinics.
- Caregiver-reported daily-life impact. Caregiver interviews captured alpha-mannosidosis-specific symptoms and concerns that generic questionnaires did not fully cover, which may help studies measure day-to-day changes that matter to families.
January 2026
- Diagnosis delay. Symptoms often began years before diagnosis was confirmed.
- Combined testing. Enzyme and genetic tests helped when brain scans differed.
- Retina changes. One long follow-up showed step-by-step retinal worsening.
Get the monthly update by email
Subscribe here to receive an email when a new monthly alpha-mannosidosis update is published. You can unsubscribe at any time. Your address is used for this only; delivery is handled by MailerLite (privacy policy).